ArticleFrontiers in immunology2025
Prognostic analysis and identification of M7G immune-related genes in lung squamous cell carcinoma.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advancing prognostic and therapeutic prediction in lung squamous cell carcinoma through integrated multi-omics analysis and 117 machine learning combinations.Journal of thoracic disease · 2025Article
- Integrated bioinformatics and machine learning identify S100A9 and VGLL1 as hub genes for schizophrenia.Frontiers in psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In recent years, the clinical application of targeted therapies and immunotherapy has significantly improved survival outcomes for patients with lung adenocarcinomas(LUAD). However, due to fewer mutations, lung squamous cell carcinomas(LUSC) shows limited efficacy with targeted and immunotherapy, resulting in a notably lower 5-year survival rate compared to lung adenocarcinoma. The m7G modification plays an important role in tumorigenesis, progression, immune evasion, and therapeutic response. This study aims to develop a novel scoring system based on m7G modification and immune status to clinically predict the prognosis of patients with LUSC and to provide new therapeutic targets. Methods: In this study, we utilized RNA-seq data from the TCGA-LUSC database as the training set and GSE50081 from the GEO database as the validation set. Immunotherapy data were obtained from the IMMPORT database, and m7G data from previous research. Using bioinformatics, we developed a prognostic model for LUSC based on m7G pathway-related immune gene characteristics. We analyzed the correlation between the prognostic model and clinical pathological features of LUSC, as well as the model's independent prognostic capability. Subsequently, patients were divided into high-risk and low-risk groups, and we examined the differences in enriched pathways, immune cell infiltration correlations, and drug sensitivity between the two groups. Results: The m7G immune-related genes FGA, CSF3R, and ORM1 increase the survival risk in patients with lung squamous cell carcinoma, whereas NTS exerts a protective effect. The prognostic risk model for lung squamous cell carcinoma (LUSC) based on m7G immune-related gene expression demonstrates that the overall survival of the high-risk group is significantly poorer than that of the low-risk group. Conclusion: The risk model developed based on m7G immune-related genes can help predict the clinical prognosis of LUSC patients and guide treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.